Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Treatment and prevention of seizures in preeclampsia/eclampsia,Management of acute hypomagnesemia,Treatment of life-threatening ventricular arrhythmias (e.g., torsade de pointes),Off-label: acute asthma exacerbation, tetanus, and constipation
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Magnesium sulfate is primarily excreted unchanged by the kidneys. It does not undergo significant hepatic metabolism.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Approximately 30–40% bound to albumin.
Low protein binding; 0–11% bound, primarily to albumin.
0.2–0.3 L/kg. Distributes mainly in extracellular fluid; crosses placenta and blood-brain barrier.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
IV: 100%. IM: ~80% (variable). Oral: <20% (poor, due to limited absorption; primarily used for catharsis).
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
GFR <20 m L/min: maximum dose 2 g; avoid use if anuria. GFR 20-50 m L/min: reduce dose by 25-50%.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Child-Pugh Class B or C: reduce dose by 50% and monitor serum magnesium levels.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
IV: 20-40 mg/kg/dose (max 2 g) as 10% solution; for severe hypomagnesemia: 25-50 mg/kg/dose q4-6h.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Reduce initial dose by 25-50%; infuse over longer period; monitor renal function and serum magnesium closely.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Continuous infusion of magnesium sulfate can cause hypermagnesemia, which may lead to respiratory depression or cardiac arrest. Only use with continuous monitoring of serum magnesium levels and clinical status.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of hypermagnesemia, especially in renal impairment; monitor serum magnesium levels, deep tendon reflexes, and respiratory rate; use with caution in patients with myasthenia gravis or heart block; avoid extravasation due to risk of tissue necrosis.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypersensitivity to magnesium sulfate; heart block or myocardial damage; severe renal impairment (anuria or oliguria); hypermagnesemia.
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No specific food interactions. However, high dietary magnesium intake from supplements or foods may increase risk of toxicity when receiving magnesium sulfate. Maintain adequate hydration.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Prolonged use (≥5-7 days) in pregnancy is associated with fetal hypocalcemia, skeletal demineralization, and neonatal hypermagnesemia. No increased risk of major malformations with standard short-term use. Third trimester: risk of neonatal hypotonia, respiratory depression if given near delivery. Continuous infusion for tocolysis >48 hours increases risk of neonatal bone abnormalities.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Magnesium is excreted into breast milk; estimated infant dose approximately 1-2% of maternal weight-adjusted dose. M/P ratio not established. Risk of infant diarrhea and hypotonia with high maternal doses. Avoid prolonged high-dose therapy during breastfeeding.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Increased renal clearance in pregnancy may necessitate higher doses to maintain therapeutic magnesium levels. Monitor serum magnesium levels closely and adjust infusion rate accordingly (usual loading dose 4-6 g IV, maintenance 1-2 g/h). In preeclampsia/eclampsia, target serum magnesium 4-7 m Eq/L.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Magnesium sulfate is first-line for eclampsia and severe preeclampsia. Monitor for loss of deep tendon reflexes (DTRs) as early sign of toxicity; DTRs disappear at ~10 m Eq/L serum magnesium. Calcium gluconate is the antidote for magnesium toxicity. Use with caution in renal impairment; dose adjustment recommended. IV administration can cause hypotension and bradycardia. Not compatible with solutions containing calcium; may precipitate.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Report any muscle weakness, difficulty breathing, or extreme drowsiness immediately.,You may experience warmth, flushing, or sweating during IV infusion.,Avoid driving or operating heavy machinery until effects are known.,Inform your doctor if you have kidney disease, heart block, or are taking other medications.,Use during pregnancy is typically under close monitoring; discuss risks and benefits.,Do not suddenly stop taking magnesium sulfate; follow prescribed tapering schedule.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Felbamate, an antiepileptic drug, potentiates the central nervous system (CNS) depressant effects of magnesium sulfate, a tocolytic and anticonvulsant agent. This additive pharmacodynamic interaction can lead to excessive sedation, respiratory depression, and impaired motor coordination. Clinically, concurrent use may exacerbate hypotonia, hyporeflexia, and somnolence, particularly in patients with renal impairment or those receiving high doses."
"Coadministration of Clevidipine, a dihydropyridine calcium channel blocker, and Magnesium sulfate, which acts as a physiological calcium antagonist, potentiates the hypotensive and negative inotropic effects due to additive inhibition of calcium influx into cardiac and vascular smooth muscle cells. This can lead to exaggerated reductions in blood pressure, bradycardia, and impaired cardiac contractility, particularly in patients with pre-existing cardiovascular compromise. Severe hypotension and heart block have been reported, especially during intravenous administration of both agents."
"The combination of nicardipine, a calcium channel blocker, and magnesium sulfate, a calcium antagonist, synergistically reduces vascular smooth muscle contractility and myocardial conduction. This additive pharmacodynamic effect can lead to profound hypotension, bradycardia, and impaired cardiac contractility, particularly in patients with pre-existing cardiovascular compromise. Clinically, patients may experience symptomatic hypotension, dizziness, or syncope, and in severe cases, cardiovascular collapse may occur."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAGNESIUM SULFATE IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
MAGNESIUM SULFATE IN PLASTIC CONTAINER is a Electrolyte that works by Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAGNESIUM SULFATE IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAGNESIUM SULFATE IN PLASTIC CONTAINER is: IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAGNESIUM SULFATE IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAGNESIUM SULFATE IN PLASTIC CONTAINER is classified as Category C. Prolonged use (≥5-7 days) in pregnancy is associated with fetal hypocalcemia, skeletal demineralization, and neonatal hypermagnesemia. No increased risk of major malformations with. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.